Disclosed is the use of an effective amount of an oral dosage of a nonsystemic topical active corticosteroid sufficient to expose a metabolite of the non-systemic topical corticosteroid to the pulmonary circulation of a subject for the manufacture of a medicament for treatment of an interstitial lung disease, wherein the topical active corticosteroid is beclomethasone dipropionate and the metabolite is 17-beclomethosone monopropionate.